Rayburn West Financial Services LLC Takes $1.17 Million Position in Merck & Co., Inc. $MRK

Rayburn West Financial Services LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 11,144 shares of the company’s stock, valued at approximately $1,173,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Chesapeake Wealth Management increased its holdings in shares of Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after acquiring an additional 87 shares during the period. Westside Investment Management Inc. increased its holdings in shares of Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after acquiring an additional 93 shares during the period. Valued Wealth Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 26.9% in the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after acquiring an additional 94 shares during the period. Payne Capital LLC increased its holdings in shares of Merck & Co., Inc. by 0.9% in the 4th quarter. Payne Capital LLC now owns 10,637 shares of the company’s stock valued at $1,120,000 after acquiring an additional 97 shares during the period. Finally, Abound Wealth Management increased its holdings in shares of Merck & Co., Inc. by 6.8% in the 4th quarter. Abound Wealth Management now owns 1,554 shares of the company’s stock valued at $164,000 after acquiring an additional 99 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts and market commentary highlighted that Keytruda drove Merck’s strong first-quarter sales, with revenue topping expectations and sales around $8 billion, reinforcing the drug’s importance to MRK’s 2026 growth outlook. Article Title
• Positive Sentiment: Merck said it will present new long-term oncology data and more than 100 abstracts at ASCO 2026, which could keep investor focus on the strength of its cancer portfolio and pipeline. Article Title
• Positive Sentiment: Merck broadened KEYTRUDA collaboration efforts with partners including Erasca and Inhibrx, signaling continued pipeline development around combination therapies as the company prepares for eventual patent-expiry pressure. Article Title
• Neutral Sentiment: One analyst reinstated Merck with a “Neutral” rating and a $125 price target, suggesting the stock may be fairly valued near current levels rather than clearly undervalued or overvalued. Article Title
• Neutral Sentiment: A valuation-focused article noted mixed recent share performance, including short-term weakness despite strong longer-term returns, which may be tempering enthusiasm even as fundamentals remain solid. Article Title

Merck & Co., Inc. Stock Up 1.1%

Shares of MRK stock opened at $113.57 on Thursday. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The stock’s fifty day moving average price is $116.31 and its 200 day moving average price is $109.01. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company has a market cap of $280.49 billion, a price-to-earnings ratio of 31.99, a price-to-earnings-growth ratio of 2.53 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the business earned $2.22 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MRK has been the topic of a number of analyst reports. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target on the stock. Barclays started coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 target price on the stock. Cantor Fitzgerald boosted their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Wells Fargo & Company dropped their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, UBS Group boosted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.